Table 4 Assessment administration time points, target respondents, and frequency. Measurement tools including the type of data, key respondents, frequency, and time points of administration
From: Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol
Survey topic | Method | Respondent(s) | Frequency | Time point(s) |
|---|---|---|---|---|
Hospital assessment questionnaire | QUAN | LMIC site physician champion | 1 time | Prior to BHAP enrollment |
Complexity assessment | QUAN | Implementation team | 4 times | Pre-training, 3 and 6Â months, and 1-year post-training |
Implementation Climate Scale (ICS) | QUAN | |||
Organization Readiness for Implementing Change (ORIC) | QUAN | |||
Acceptability of intervention (AIM) | QUAN | |||
Intervention Appropriateness Measures (IAM) | QUAN | |||
Feasibility of Intervention (FIM) | QUAN | |||
Knowledge assessment: nurses | QUAN | All nurses | 4 times | Pre-training, 3 and 6Â months, and 1Â year post-training |
Knowledge assessment: pharmacy | QUAN | All pharmacists | ||
Knowledge assessment: physician | QUAN | All physicians | ||
Training material feedback survey | QUAL | Implementation team | 1 time | 3Â months post-training (after the 1st patient received blinatumomab) |
Semi-structured group interviews: 1) Training program feedback and site-specific barriers 2) Site-specific fidelity vs adaptation | QUAL | Implementation team | 2 times | 3Â months post-training (after the 1st patient received blinatumomab) and 12Â months post-training |
Implementation strategy feedback | QUAN | Key stakeholders (implementation team, industry, St. Jude) | 1 time | Annual review |
Program evaluation group interview | QUAL | |||
1 time | Annual review |